Recent advancements in cancer immunotherapy highlight the potential of vaccines that harness the body’s immune response to combat tumors. While several vaccines have received FDA approval for specific cancers, many patients experience insufficient immune activation. To address this challenge, researchers have explored various methods, including the simultaneous administration of immune-stimulating molecules known as cytokines. However, this approach often leads to significant side effects.
A team of scientists, including MIT chemical engineer Daniel Anderson, has unveiled a groundbreaking strategy to enhance the T-cell response to mRNA vaccines. This innovative technique could significantly improve the efficacy of cancer vaccines and bolster defenses against infectious diseases. The researchers developed a novel adjuvant—a substance that enhances the immune response—comprising mRNA molecules that encode genes capable of activating immune cells by initiating specific signaling pathways.
In preclinical studies involving mouse models of various cancers, including bladder cancer and melanoma, the injection of lipid nanoparticles containing the mRNA adjuvant demonstrated remarkable results. The immune systems of these mice exhibited a notable ability to slow tumor growth and, in some cases, completely eliminate tumors. Remarkably, this enhancement occurred even in the absence of a specific cancer vaccine; however, the response intensified when the vaccine was administered. According to Anderson, incorporating these adjuvant mRNAs into vaccines significantly increases the number of antigen-targeted T cells, which are crucial for a robust immune response. Moreover, this adjuvant improved responses to checkpoint blockade inhibitors, a class of immunotherapy drugs approved for various cancer treatments.
Christopher Garris, a senior author of the study and assistant professor at Harvard Medical School, emphasized that the hostile environment surrounding solid tumors often hampers T-cell effectiveness. The findings suggest that immune remodeling facilitated by these adjuvants can create a more favorable setting for T cells, encouraging tumor rejection. Additionally, the team investigated the adjuvant’s potential to enhance immune responses against viral infections. When combined with COVID-19 or influenza vaccines, the mRNA particles produced a T-cell response that was 10 to 15 times stronger than the typical response.
Looking ahead, the researchers plan to further investigate this approach across various animal models, aiming to refine its application for both cancer treatment and infectious disease prevention. Meanwhile, other teams at MIT are also making strides with adjuvants; for instance, Ana Jaklenec’s group is working on an adjuvant to enhance the injectable polio vaccine’s efficacy in stimulating a strong mucosal immune response in the gastrointestinal tract, which is crucial for reducing viral transmission during polio eradication efforts.
Source: Amping up T cells to target cancer via MIT Technology Review